ALFA Finder| Revenue growth | ₹4,670.81 lakh (+89.59% YoY) in FY26. |
|---|---|
| Margins | EBITDA margin at 16.06% in FY26 vs 19.31% in FY25. |
| Demand visibility | Strong; 50k+ prescriptions per day and 10k+ doctors. |
| Management confidence | High; aiming for global footprint by 2030. |
Growth
FY26 Revenue reached ₹4,670.81 lakh (+89.59% YoY); EBITDA at ₹750.32 lakh (+57.73% YoY); PAT at ₹461.99 lakh (+49.05% YoY).
Outlook
Targets 500+ products in 3 years; pan-India expansion by 2029; launching new Mindcare and Orbit divisions.
Risks
Dependence on contract manufacturers; competitive pharmaceutical market; regulatory compliance across diverse geographies.
Earnings Call filed with BSE, BSE: 544529. Summary written with AI assistance from the document.
Aptus Pharma Ltd: key numbers
- Share price
- ₹480.00
- Market cap
- ₹823.2 Cr
- Revenue (annual)
- ₹46.57 Cr
- Net profit (annual)
- ₹4.62 Cr
- P/E (TTM)
- 178.2×Sector 43.8×
- Promoter holding
- 72.89%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aptus Pharma Ltd
All →Aptus Pharma Preferential Issue
Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.
- Value
- ₹44.78 Cr
Aptus Pharma Investor Presentation: Key Takeaways
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma H1 FY27 Results: Net Profit ₹5.1 Cr, Up 200.0% YoY
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.1 Cr · +200.0% YoY
Aptus Pharma Other Announcement
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.
Aptus Pharma Annual General Meeting
Aptus Pharma Ltd issued a corrigendum to its 16th AGM notice regarding inadvertent errors in the explanatory statement for item no. 3.
Aptus Pharma Fund Raise of ₹44.88 Cr
Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
- Value
- ₹44.88 Cr
- Execution
- 36 months